# Phase 1 prostatic cancer trials recruiting: 83 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 83 trials in phase 1 for prostatic cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 prostatic cancer trials: 83 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/prostatic-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 83
- Recruiting or not yet: 83
- Read on: November 19, 2026

## Trials

The 25 newest of 83, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07940023 | Bispecific PSMAxCD3 Antibody CC-1 Applied Subcutaneously in Patients With Castration Resistant Prostate Carcinoma | University Hospital Tuebingen | Phase 1 | Not yet recruiting | Castration Resistant Prostate Cancer, Prostate Cancer | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940023) |
| October 22, 2026 | NCT07887971 | A Study of \[225Ac\]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors | Aktis Oncology, Inc. | Phase 1 | Recruiting | NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer), ES-SCLC, Small Cell Lung Cancer Extensive Stage, B7H3, Prostate... | 152 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887971) |
| October 6, 2026 | NCT07860255 | Testing Pasritamig Before Surgery for the Treatment of Localized Prostate Cancer | Fred Hutchinson Cancer Center | Phase 1 | Not yet recruiting | Prostate Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07860255) |
| September 10, 2026 | NCT07813637 | Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC | Janux Therapeutics | Phase 1 | Recruiting | Prostate Cancer, Castration-Resistant Prostate Cancer (CRPC), Metastatic Prostate Cancer, Metastatic... | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07813637) |
| September 4, 2026 | NCT07803653 | IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate Cancer | Fred Hutchinson Cancer Center | Phase 1 | Not yet recruiting | Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07803653) |
| August 24, 2026 | NCT07783282 | A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer | Astellas Pharma Global Development, Inc. | Phase 1 | Recruiting | Prostate Cancer | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783282) |
| August 10, 2026 | NCT07756593 | Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer | Washington University School of Medicine | Phase 1 | Not yet recruiting | Prostate Cancer, Metastatic Prostate Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07756593) |
| August 5, 2026 | NCT07746713 | A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer | Janssen Research & Development, LLC | Phase 1 | Recruiting | Prostatic Neoplasms | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07746713) |
| July 30, 2026 | NCT07735377 | A Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-6914 Injection... | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 | Recruiting | Prostate Cancer | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07735377) |
| July 22, 2026 | NCT07719361 | A Study in Patients With Metastatic Castration-Resistant Prostate Cancer | Flare Therapeutics Inc. | Phase 1 | Recruiting | Metastatic Castration Resistant Prostate Cancer, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer)... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07719361) |
| July 17, 2026 | NCT07711184 | A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | Recruiting | Prostate Cancer | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07711184) |
| July 6, 2026 | NCT07682649 | Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer | University of Michigan Rogel Cancer Center | Phase 1 | Not yet recruiting | Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07682649) |
| June 22, 2026 | NCT07661641 | A Study of \[177Lu\]Lu-A9-0631 and \[225Ac\]Ac-A9-0642 With \[68Ga\]Ga-A9-6217 or \[177Lu\]Lu-A9-0631 Imaging in GRPR+ Solid Tumors | Alpha-9 Oncology USA Inc. | Phase 1 | Recruiting | Breast Cancer, Prostate Cancer, Colorectal Cancer, GRPR-positive Solid Tumors | 115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07661641) |
| June 11, 2026 | NCT07641049 | Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer | Beijing Biotech | Phase 1 | Recruiting | Metastatic Castration-resistant Prostate Cancer, Advanced Prostate Adenocarcinoma, PSCA-positive Prostate Cancer... | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07641049) |
| June 9, 2026 | NCT07636707 | QLF4113 in Participants With Metastatic Prostate Cancer | Qilu Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Prostate Cancer | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07636707) |
| May 12, 2026 | NCT07581184 | A Study of \[225Ac\]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer | Aktis Oncology, Inc. | Phase 1 | Recruiting | Castration Resistant Metastatic Prostate Cancer, Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate... | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07581184) |
| May 6, 2026 | NCT07570979 | A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor... | Novartis Pharmaceuticals | Phase 1 | Recruiting | Metastatic Castration-resistant Prostate Cancer (mCRPC) | 208 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07570979) |
| April 22, 2026 | NCT07545811 | Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer | Janux Therapeutics | Phase 1 | Recruiting | Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07545811) |
| April 21, 2026 | NCT07543055 | A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and... | Regeneron Pharmaceuticals | Phase 1 | Recruiting | Prostate Cancer | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07543055) |
| April 8, 2026 | NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Phase 1 | Recruiting | Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07517198) |
| March 27, 2026 | NCT07495293 | Ultra-hypofractionated Carbon-ion Therapy for Prostate Cancer | Yonsei University | Phase 1 | Not yet recruiting | Prostate Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07495293) |
| March 25, 2026 | NCT07493512 | Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer | Amgen | Phase 1 | Recruiting | Metastatic Castration-resistant Prostate Cancer (mCRPC) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07493512) |
| March 12, 2026 | NCT07468396 | A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer | Gan & Lee Pharmaceuticals. | Phase 1 | Not yet recruiting | Prostate Cancer | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07468396) |
| February 20, 2026 | NCT07424547 | Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors | Conjupro Biotherapeutics, Inc. | Phase 1 | Recruiting | Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer, Prostate, Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer | 386 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07424547) |
| January 22, 2026 | NCT07358806 | Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors | Oscotec Inc. | Phase 1 | Recruiting | Solid Tumor, Breast Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Gastric/Gastroesophageal... | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07358806) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 4 |
| [Astellas Pharma Global Development, Inc.](https://specstream.ai/data/clinical-trials/company/astellas-pharma-global-development-inc) | 4 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 3 |
| Janux Therapeutics | 3 |
| Aktis Oncology, Inc. | 2 |
| University Hospital Tuebingen | 2 |
| City of Hope Medical Center | 2 |
| Fred Hutchinson Cancer Center | 2 |
| [Jiangsu Hansoh Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hansoh-pharmaceutical-co-ltd) | 2 |
| Hangzhou DAC Biotechnology Co., Ltd. | 2 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 2 |
| [Jiangsu HengRui Medicine Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hengrui-medicine-co-ltd) | 2 |
| MOMA Therapeutics | 1 |
| Yonsei University | 1 |
| Conjupro Biotherapeutics, Inc. | 1 |
| Flare Therapeutics Inc. | 1 |
| Instituto do Cancer do Estado de São Paulo | 1 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 1 |
| Zumutor Biologics Inc. | 1 |
| Shanghai AbelZeta Ltd. | 1 |
| [Genentech, Inc.](https://specstream.ai/data/clinical-trials/company/genentech-inc) | 1 |
| Nammi Therapeutics Inc | 1 |
| ViroMissile, Inc. | 1 |
| Angiex, Inc. | 1 |
| M.D. Anderson Cancer Center | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 57 |
| China | 21 |
| Australia | 15 |
| Spain | 9 |
| United Kingdom | 9 |
| Germany | 6 |
| Japan | 6 |
| France | 5 |
| South Korea | 5 |
| Canada | 4 |
| Brazil | 1 |
| Portugal | 1 |
| Switzerland | 1 |
| Taiwan | 1 |
| South Africa | 1 |
| Norway | 1 |
| Bulgaria | 1 |
| Italy | 1 |
| Puerto Rico | 1 |
| Israel | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Lumber stores in the United States](https://specstream.ai/data/businesses/lumber-stores/united-states)
- [Fire protection companies in the United States](https://specstream.ai/data/businesses/fire-protection-companies/united-states)
- [Caterers in the United States](https://specstream.ai/data/businesses/caterers/united-states)
- [Woodworking supply stores in the United States](https://specstream.ai/data/businesses/woodworking-supply-stores/united-states)
- [Salad bars in the United States](https://specstream.ai/data/businesses/salad-bars/united-states)
- [Metal plating companies in the United States](https://specstream.ai/data/businesses/metal-plating-companies/united-states)
